PCT WORLD ORGANISATION FOR INTELLECTUAL PROPERTY
International Office
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification[6] : C07D 209/18, 401/12, A61K 31/40

A1

(11) International publication number: WO 98/09946

(43) International publication date: 12 March 1998 (12.03.98)

(21) International application number: PCT/EP97/04474

(22) International filing date: 16 August 1997 (16.08.97)

(30) Data relating to the priority:
196 36 150.8 6 September 1996 (06.09.96) DE

(71) Applicant: ASTA MEDICA AKTIENGESELLSCHAFT [DE/DE]; An der Pikardie 10, D-01277 Dresden (DE).

(72) Inventors: Guillaume LEBAUT; 5, rue de la Baugerie, F-44230 Saint-Sébastien-sur-Loire (FR). Cécilia MENCIU; 11, rue du 4 septembre, F-44100 Nantes (FR). Bernhard KUTSCHER; Stresemannstrasse 9, D-63477 Maintal 1(DE). Peter EMIG; Ludwig-Erhardstrasse 22, D-63486 Bruchköbel (DE). Stefan SZELENYI; Haendelstrasse 32, D-90571 Schwaig (DE). Kay BRUNE; Weiherackerweg 17, D-91080 Marloffstein (DE).

(81) Designated States: AU, BR, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RU, SG, SK, TR, UA, European Patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With the International Search Report.
Before expiry of the period provided for amending the claims. Further publication will be made if such amendments are received.

As printed

(54) Title: N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT

(54) Bezeichnung: N-SUBSTITUIERTE INDOL-3-GLYOXYLAMIDE MIT ANTIASTHMATISCHER, ANTIALLERGISCHER UND IMMUNSUPPRESSIVER/IMMUNMODULIERENDER WIRKUNG

(57) Abstract

New N-substituted indol-2-glyoxylamids, the production method and the pharmaceutical application thereof are disclosed. The inventive compounds appear to have antiasthmatic, hypoallergenic and immunosuppresive/immunomodulating properties.

(57) Zusammenfassung

Die Erfindung betrifft neue N-substituierte Indol-3-glyoxylamide, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung. Die Verbindungen weisen antiasthmatische, antiallergische und immunsuppressive/immunmodulierende Wirkungen auf.